A single center prospective study of patients aged 0-25 years with CD19+ acute leukemia who received blinatumomab
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 31 Jan 2025 New trial record
- 10 Dec 2024 Results assessing changes in TCR signaling, T-cell memory subsets, and T-cell function during a 28-day blinatumomab cycle in pediatric CD19+ leukemia with low burden disease, presented at the 66th American Society of Hematology Annual Meeting and Exposition.